Does PALBOCICLIB Cause Neoplasm malignant? 373 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 373 reports of Neoplasm malignant have been filed in association with PALBOCICLIB (Ibrance). This represents 0.4% of all adverse event reports for PALBOCICLIB.
373
Reports of Neoplasm malignant with PALBOCICLIB
0.4%
of all PALBOCICLIB reports
38
Deaths
28
Hospitalizations
How Dangerous Is Neoplasm malignant From PALBOCICLIB?
Of the 373 reports, 38 (10.2%) resulted in death, 28 (7.5%) required hospitalization, and 2 (0.5%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 373 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which PALBOCICLIB Alternatives Have Lower Neoplasm malignant Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID